Shenyang Xingqi Pharmaceutical Co Ltd (300573) — Net Asset Quality Index
Shenyang Xingqi Pharmaceutical Co Ltd (300573) has a Net Asset Quality Index of 76.8% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥2.42 Billion minus total liabilities of CN¥562.18 Million yields net assets of CN¥1.86 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Also explore Shenyang Xingqi Pharmaceutical Co Ltd (300573) total assets for the complete picture of this company's asset base.
Quality Index
Net Assets
Total Assets
Total Liabilities
Shenyang Xingqi Pharmaceutical Co Ltd Net Asset Quality Index Over Time (2011–2024)
This chart shows how Shenyang Xingqi Pharmaceutical Co Ltd's Net Asset Quality Index has evolved across 14 annual periods from 2011 to 2024. As of September 2025, the index stands at 76.8%, representing net assets of CN¥1.86 Billion against total assets of CN¥2.42 Billion CNY. See Shenyang Xingqi Pharmaceutical Co Ltd current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Shenyang Xingqi Pharmaceutical Co Ltd (2011–2024)
The table below presents the year-by-year Net Asset Quality Index for Shenyang Xingqi Pharmaceutical Co Ltd from 2011 to 2024, covering 14 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see 300573 company net worth.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 74.9% | CN¥1.59 Billion | CN¥2.13 Billion | CN¥534.48 Million | ▼ -8.6 pp |
| 2023 | 83.5% | CN¥1.69 Billion | CN¥2.02 Billion | CN¥333.92 Million | ▼ -3.6 pp |
| 2022 | 87.1% | CN¥1.55 Billion | CN¥1.78 Billion | CN¥230.63 Million | ▲ +7.4 pp |
| 2021 | 79.7% | CN¥1.34 Billion | CN¥1.69 Billion | CN¥342.35 Million | ▲ +7.8 pp |
| 2020 | 71.9% | CN¥694.06 Million | CN¥965.70 Million | CN¥271.64 Million | ▲ +4.4 pp |
| 2019 | 67.4% | CN¥574.90 Million | CN¥852.37 Million | CN¥277.46 Million | ▼ -10.8 pp |
| 2018 | 78.3% | CN¥554.58 Million | CN¥708.47 Million | CN¥153.89 Million | ▼ -3.5 pp |
| 2017 | 81.8% | CN¥553.38 Million | CN¥676.48 Million | CN¥123.09 Million | ▲ +9.6 pp |
| 2016 | 72.2% | CN¥520.95 Million | CN¥721.41 Million | CN¥200.47 Million | ▲ +12.3 pp |
| 2015 | 59.9% | CN¥389.79 Million | CN¥650.94 Million | CN¥261.15 Million | ▲ +5.1 pp |
| 2014 | 54.8% | CN¥367.81 Million | CN¥670.90 Million | CN¥303.09 Million | ▼ -4.6 pp |
| 2013 | 59.4% | CN¥336.80 Million | CN¥567.21 Million | CN¥230.41 Million | ▼ -10.2 pp |
| 2012 | 69.5% | CN¥290.70 Million | CN¥418.02 Million | CN¥127.32 Million | ▼ -22.7 pp |
| 2011 | 92.2% | CN¥247.00 Million | CN¥267.88 Million | CN¥20.88 Million | — |